Our Products

Tazofort Syrup,Tab and Injection



Tazofort Syrup,Tab and Injection
Cefuroxime axetil
Cefuroxime axetil is the 1
-(acetyloxy)ethyl ester of cefuroxime. Its chemical name is (RS)-1-hydroxyethyl(6R,7R–7[2(2-furyl)glyoxylamido]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo [4.2.0]-oct-2-ene-2-carboxylate, 72)–(Z)–(O-methyoxime), 1-acetate 3-carbamate. Its molecular formula is C20H22N4O10S, and it has a molecular weight of 510.48.Cefuroxime axetil is
in the amorphous form.
Cefuroxime axetil is a semisynthetic cephalosporin. It is a prodrug which owes its
in vivobactericidal activity to the release of the active compound cefuroxime.
Cefuroxime has bactericidal activity against a wide range of common pathogens, including
Beta-lactamase producing strains. The bactericidal action of cefuroxime results from
inhibition of cell wall synthesis by binding to essential target proteins. Cefuroxime has good
stability to bacterial beta-lactamase


Cefuroxime has been shown to be usually active against the following organisms
in vitroand in clinical studies:
Aerobes Gram-negative:
Escherichia coli
Haemophilus influenzae
(including ampicillin-resistant strains)
Haemophilus parainfluenzae
Neisseria gonorrhoeae
(non-penicillinase producing strains)
Aerobes Gram-positive
Staphylococcus aureusand Staphylococcusepidermidis
(including penicillinase producing strains butexcluding methicillin resistant strains)
Streptococcus pyogenes(and other beta-haemolytic streptococci)
Streptococcus pneumonia,Streptococcus Group B (Streptococcus agalactiae)
The following organisms are not susceptible to Cefuroxime:
Clostridium difficile
Pseudomonas spp
Campylobacter spp
Methicillin resistant strains ofStaphylococcus aureus and Staphylococcus epidermidis
Proteus vulgaris
Morganella morganii
Serratia spp
Bacteroides fragilis
Most strains of
Streptococcus faecalis
Citrobacter spp
Enterobacter spp

 Susceptibility Tests
Diffusion Techniques
Quantitative methods that require measurement of zone diameters give the most precise
estimate of antibiotic susceptibility. One such standard procedure that has been
recommended for use with disks to test susceptibility of organisms to cefuroxime uses the
30mcg cefuroxime disk. Interpretation involves the correlation of the diameters obtained in
the disk test with the minimum inhibitory concentration (MIC) for cefuroxime.
Reports from the laboratory giving results of the standard single-
disk susceptibility test with a 30mcg cefuroxime disk should be interpreted according to the following criteria:
After oral administration cefuroxime axetil is absorbed from the
gastrointestinal tract and rapidly hydrolysed in the body to release cefuroxime into the circulation. Approximately 60% of an administered dose is absorbed. Optimum absorption occurs when it is administered after a light meal. Absorption is not decreased by drugs which affect gastrointestinal motility eg loperamide, diphenoxylate or castor oil. However, absorption is decreased by concurrent administration of drugs such as ranitidine.
The mean peak serum level of cefuroxime following a 250mg dose in normal healthy adults, after food, was 4.1mg/L and occurred two to three hours after dosing. Serum levels were
significantly higher in the elderly, apparently due to slower excretion. Unhydrolysed drug has not been detected in the serum but 1-2% of the administered dose is excreted in the urine in a form which indicates that small amounts of the intact ester are absorbed into circulation. The mean serum half life of cefuroxime is approximately 1.2 hours. Protein binding has been variously stated as 33-50% depending on the methodology used. Cefuroxime is not metabolised to any significant extent.
Excretion occurs mainly through the kidney both by glomerular filtration and tubular secretion.
Approximately 49% of an administered dose, after food, is recovered in the urine in 24 hours; urinary recovery is significantly reduced if the drug is taken on an empty stomach. After a 250mg dose urinary concentrations at 0-6 and 6-12 hours were 227mcg/mL (range92-515) and 35.3mcg/mL (range 7.6-102) respectively.
Concurrent administration of probenecid prolongs the terminal half life of cefuroxime. Serum
levels of cefuroxime are reduced by haemodialysis.
Cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria.
Acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis.
Acute exacerbations of chronic bronchitis, or acute bronchitis.
Skin and skin structure infections for example, furunculosis, pyoderma and impetigo.
Acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.
Patients with known hypersensitivity to cephalosporin antibiotics or who have experienced a
major allergy to penicillin (anaphylaxis, angioneurotic oedema, urticaria)

The usual course of therapy with TAZOFORT tablets is 5 to 7 days for treatment of bronchitis, and 7 to 10 days for other infections.
Cefuroxime axetil should be taken after a light meal for optimum absorption.
Acute exacerbations of chronic bronchitis-250mg to 500 mg twice daily
Acute bronchitis-250mg to 500mg twice daily
Uncomplicated gonococcal urethritis or cervicitis-single dose of 1g
Other infections-250 mg twice daily

When stored below 30°C TAZOFORT tablets have a 3 year shelf life.
TAZOFORT Tablets 500 mg: White, film coated, capsule shaped, biconvex tablets. Each tablet contains cefuroxime (as axetil) 500 mg in foil blisters of 2*7
TAZOFORTtablets also contain cellulose-microcrystalline, croscarmellose sodium, hypromellose, methyl hydoxybenzoate, Opaspray White M-1-7120, propylene glycol, propyl
hydroxybenzoate, silica-colloidal anhydrous, sodium laurylsulphate and hydrog

Also available as :
125,g/5ml in 100ml bottle


© 2016 Milton Pharma International . All rights reserved | Design by Hans Finest Solutions